Principles of diagnosis and treatment of post-traumatic neurogenic lower urinary tract dysfunction

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

This article provides an overview of modern approaches to the diagnosis and treatment of post-traumatic neurogenic lower urinary tract dysfunction. Lower urinary tract dysfunction is observed in nearly all patients with traumatic brain or spinal cord injuries. It is noted that the type of urodynamic impairment does not always correspond to the level and severity of nervous system damage. The clinical diversity of neurogenic lower urinary tract dysfunction resulting from traumatic central nervous system injuries is highlighted, necessitating thorough evaluation, including urodynamic studies. The selection of treatment methods for patients is discussed in detail, depending on the type of neurogenic lower urinary tract dysfunction.

作者简介

Aleksander Nikolaev

Kirov Military Medical Academy

编辑信件的主要联系方式.
Email: alex.urology@yandex.ru
ORCID iD: 0009-0008-0593-4562
俄罗斯联邦, Saint Petersburg

Vladimir Protoshchak

Kirov Military Medical Academy

Email: protoshakurology@mail.ru
ORCID iD: 0000-0002-4996-2927
SPIN 代码: 6289-4250

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Saint Petersburg

Mikhail Paronnikov

Kirov Military Medical Academy

Email: paronnikov@mail.ru
ORCID iD: 0009-0005-1762-6100
SPIN 代码: 6147-7357

MD, Dr. Sci. (Medicine)

俄罗斯联邦, Saint Petersburg

Pavel Babkin

Kirov Military Medical Academy

Email: pavelbabkin@yandex.ru
SPIN 代码: 6551-4494

MD, Dr. Sci. (Medicine)

俄罗斯联邦, Saint Petersburg

Nikolai Kushnirenko

Kirov Military Medical Academy

Email: nikolaj.kushnirenko@yandex.ru
ORCID iD: 0009-0004-1960-4696
SPIN 代码: 3892-8959

MD, Dr. Sci. (Medicine)

俄罗斯联邦, Saint Petersburg

Pavel Kislitsyn

Kirov Military Medical Academy

Email: pavelkislitsinmd@gmail.com
ORCID iD: 0009-0007-5949-3902
SPIN 代码: 8965-7814
俄罗斯联邦, Saint Petersburg

参考

  1. Russian Society of Urologists. Neurogenic dysfunction of the lower urinary tract. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020 [cited 2024 May 25] Available at: https://cr.minzdrav.gov.ru/sche-ma/588_2 (In Russ.)
  2. Fitzharris M, Cripps RA, Lee BB. Estimating the global incidence of traumatic spinal cord injury. Spinal Cord. 2014;52(2):117–122. doi: 10.1038/sc.2013.135
  3. Grin’ AA. Surgical treatment of patients with spinal cord and spinal cord injury in combined trauma [dissertation]. Moscow; 2008 [cited 2024 May 05]. Available from: https://rusneb.ru/catalog/000199_000009_003165607 (In Russ.)
  4. Lobzin SV, Mirzaeva LM, Tcinzerling NV, et al. Acute traumatic spinal cord injury in saint petersburg. epidemiological data: incidence rate, gender and age characteristics. Herald of North-Western State Medical University named after I.I. Mechnikov. 2019;11(2):27–34 EDN: GKMUGT doi: 10.17816/mechnikov201911227-34
  5. Kumar R, Lim J, Mekary RA, et al. Traumatic spinal injury: global epidemiology and worldwide volume. World Neurosurg. 2018;113: e345–e363. doi: 10.1016/j.wneu.2018.02.033
  6. Military field surgery. National Manual. Samohvalov IM, editor. 2nd edition. Moscow: GEOTAR-Media; 2024. 1056 p. (In Russ.) doi: 10.33029/9704-8036-6-VPX-2024-1-1056
  7. Kulaklı F, Koklu K, Ersoz M, Ozel S. Relationship between urinary dysfunction and clinical factors in patients with traumatic brain injury. Brain Inj. 2014;28(3):323–327. doi: 10.3109/02699052.2013.865268
  8. Hamid R, Averbeck MA, Chiang H, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36(10):1517–1527. doi: 10.1007/s00345-018-2301-z
  9. Saliukov RV, Bushkov FA, Novoselova IN, Yurasov IS. Urinary disorders in spinal trauma: features of diagnosis and treatment. Urology reports (St. Petersburg). 2019;9(1S):83–85. (In Russ.) EDN: ZDQALB
  10. Avdoshin VP, Aslamazov EA, Goryunov VG. Manual of Urology: in 3 vol. Lopatkin NA, editor. Mosсow: Medicina; 1998. 764 p. (In Russ.)
  11. Madersbacher H. Diagnosis of functional neurogenic urination disorders from the urologist’s viewpoint. Gynakol Rundsch. 1980;20(Suppl 2):161–172. (In German)
  12. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720–732. doi: 10.1016/S1474-4422(15)00070-8
  13. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19(10 Suppl):s191–s196.
  14. Blok B, Castro-Diaz D, Del Popolo G, et al. Neuro-Urology. Guideline of European Urological Association. 2024 [cited 2024 July 01]. Available from: https://uroweb.org/guideline/neuro-urology
  15. Ivanov VYu, Malkhasyan VA, Semenyakin IV, Pushkar DYu. Stones in the urinary bladder and their endoscopic treatment. A contemporary approach. Experimental and Clinical Urology. 2017;(3):44–50. EDN: XDVBWQ
  16. Honjo H, Kawauchi A, Nakao M, et al. Impact of convenience void in a bladder diary with urinary perception grade to assess overactive bladder symptoms: a community-based study. Neurourol Urodyn. 2010;29(7):1286–1289. doi: 10.1002/nau.20874
  17. Philippova ES, Bazhenov IV, Volkova LI, et al. Russian version of the neurogenic bladder symptom score (NBSS). Urologiia. 2018;(6): 5–13. EDN: VTPGVW doi: 10.18565/urology.2018.6.5-13
  18. Welk B, Morrow S, Madarasz W, et al. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014;192(2): 452–457. doi: 10.1016/j.juro.2014.01.027
  19. Konovalov NA, Pushkar DYu, Lysachev DA, Dzyubanova NA. Neurosurgery and urology. Moscow: GEOTAR-Media; 2022. 192 p. (In Russ.) EDN: WJCQEM
  20. Goldmark E, Niver B, Ginsberg DA. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15(10):448. doi: 10.1007/s11934-014-0448-8
  21. Rios L, Averbeck M, Madersbacher H. Neurourology: manual for clinical practice. 2nd ed. Rio de Janeiro: Sociedade Brasileira de Urologia; 2019. 182 p.
  22. Pushkar DYu, Gadgieva ZK, Kasyan GR, et al. Good urodynamic practice: consensus on the terminology. Urologiia. 2019;(1):131–136 (In Russ.) EDN: LTGBZO doi: 10.18565/urology.2019.16.131-136
  23. Krupin VN, Belova AN. Neurourology. Moscow: Antidor; 2005. 464 p. (In Russ.) EDN: QLLIFD
  24. Vishnevsky EL, Pushkar DY, et al. Uroflowmetry. Moscow: Printed City; 2004. 220 p. (In Russ.)
  25. Pushkar DY, Kasyan GR. Functional urology and urodynamics. Moscow: GEOTAR-Media; 2013. 376 p. (In Russ.)
  26. Nitti VW. Practical Urodynamics. Philadelphia: W.B. Saunders; 1998. 295 p.
  27. Çetinel B, Önal B, Can G, et al. Risk factors predicting upper urinary tract deterioration in patients with spinal cord injury: A retrospective study. Neurourol Urodyn. 2017;36(3):653–658. doi: 10.1002/nau.22984
  28. Alyaev YG, Gadzhieva ZK, Kazilov YB. Neurogenic dysfunctions of the lower urinary tract (NDNMP). Sechenov Medical Journal. 2012;3(9):15–24. (In Russ.) EDN: SMHEZX
  29. Filippova ES, Bazhenov IV. Zyryanov AV, Zhuravlev VN. The epidemiology of neurogenic urination disciordeis. Experimental and Clinical Urology. 2020;(3):25–33. EDN: FCOPJC doi: 10.29188/2222-8543-2020-12-3-25-33
  30. Kavanagh A, Akhavizadegan H, Walter M, et al. Surveillance urodynamics for neurogenic lower urinary tract dysfunction: A systematic review. Can Urol Assoc J. 2019;13(4):133–141. doi: 10.5489/cuaj.5563
  31. Collins CW, Winters JC; American Urological Association; Society of Urodynamics Female Pelvic Medicine and Urogenital Reconstruction. AUA/SUFU adult urodynamics guideline: a clinical review. Urol Clin North Am. 2014;41(3):353–362. doi: 10.1016/j.ucl.2014.04.011
  32. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006;29(5):527–573.
  33. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int. 2008;101(8):989–994. doi: 10.1111/j.1464-410X.2008.07457.x
  34. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000;55(4):490–494. doi: 10.1016/s0090-4295(99)00553-1
  35. Jeong SJ, Cho SY, Oh SJ. Spinal cord/brain injury and the neurogenic bladder. Urol Clin North Am. 2010;37(4):537–546. doi: 10.1016/j.ucl.2010.06.005
  36. Kaplan SA, Chancellor MB, Blaivas JG. Bladder and sphincter behavior in patients with spinal cord lesions. J Urol. 1991;146(1): 113–117. doi: 10.1016/s0022-5347(17)37727-3
  37. Rapidi CA, Petropoulou K, Galata A, et al. Neuropathic bladder dysfunction in patients with motor complete and sensory incomplete spinal cord lesion. Spinal Cord. 2008;46(10):673–678. doi: 10.1038/sc.2008.16
  38. Gómez RG, Elliott SP. Urologic Management of the Spinal Cord Injured Patient. World J Urol. 2018;36(10):1515–1516. doi: 10.1007/s00345-018-2467-4
  39. Jeong SJ, Cho SY, Oh SJ. Spinal cord/brain injury and the neurogenic bladder. Urol Clin North Am. 2010;37(4):537–546. doi: 10.1016/j.ucl.2010.06.005
  40. Kriz J, Sediva K, Maly M. Causes of death after spinal cord injury in the Czech Republic. Spinal Cord. 2021;59(7):814–820. doi: 10.1038/s41393-020-00593-2
  41. Elmelund M, Oturai PS, Toson B, Biering-Sørensen F. Forty-five-year follow-up on the renal function after spinal cord injury. Spinal Cord. 2016;54(6):445–451. doi: 10.1038/sc.2015.242
  42. Li GP, Wang XY, Zhang Y. Efficacy and safety of onabotulinumtoxina in patients with neurogenic detrusor overactivity caused by spinal cord injury: a systematic review and meta-analysis. Int Neurourol J. 2018;22(4):275–286. doi: 10.5213/inj.1836118.059
  43. Everaert K, Lumen N, Kerckhaert W, et al. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg. 2009;64(4):335–340. doi: 10.1179/acb.2009.052
  44. Pannek J, Kurmann C, Krebs J, et al. Changes in bacterial spectrum and resistance patterns over time in the urine of patients with neurogenic lower urinary tract dysfunction due to spinal cord injury. Urol Int. 2021;105(5–6):483–489. doi: 10.1159/000512884
  45. Šámal V, Paldus V, Fáčková D, et al. The prevalence of antibiotic-resistant and multidrug-resistant bacteria in urine cultures from inpatients with spinal cord injuries and disorders: an 8-year, single-center study. BMC Infect Dis. 2022;22(1):239. doi: 10.1186/s12879-022-07235-3
  46. Saini M, Kataruka M, Gogoi B, et al. Incidence of renal tract abnormalities on ultrasonography in patients with spinal cord injury: a retrospective pilot study of a military cohort undergoing long-term institutional rehabilitation. Asian Spine J. 2022;16(2):204–211. doi: 10.31616/asj.2020.0471
  47. Wu CQ, Franco I. Management of vesicoureteral reflux in neurogenic bladder. Investig Clin Urol. 2017;58(Suppl 1):S54–S58. doi: 10.4111/icu.2017.58.S1.S54
  48. Lane GI, Roberts WW, Mann R, et al. Outcomes of renal calculi in patients with spinal cord injury. Neurourol Urodyn. 2019;38(7): 1901–1906. doi: 10.1002/nau.24091
  49. Ost MC, Lee BR. Urolithiasis in patients with spinal cord injuries: risk factors, management, and outcomes. Curr Opin Urol. 2006;16(2):93–99. doi: 10.1097/01.mou.0000193376.07071.ac
  50. Stogov MV, Shchurova EN, Blyudenov DN. Potential biochemical factors for the development of urolithiasis in patients with spinal cord injuries. Urologiia. 2014;(1):10–15. (In Russ.) EDN: ZSPPFC
  51. Chen Y, DeVivo MJ, Roseman JM. Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. Spinal Cord. 2000;38(6):346–353. doi: 10.1038/sj.sc.3101008
  52. Håkansson MA, Neovius K, Norrbäck M, et al. Health care utilization and complications rates among users of hydrophilic-coated catheters. Urol Nurs. 2015;35(5):239–247.
  53. Igawa Y, Wyndaele JJ, Nishizawa O. Catheterization: possible complications and their prevention and treatment. Int J Urol. 2008;15(6):481–485. doi: 10.1111/j.1442-2042.2008.02075.x
  54. Harding CK, Lapitan MC, Arlandis S, et al. EAU Guideline. Management of non-neurogenic female lower urinary tract symptoms (LUTS). 2023. 146 p. Режим доступа: https://uroweb.org/guidelines/non-neurogenic-female-luts. Дата обращения: 02.02.2024.
  55. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62(5):816–830. doi: 10.1016/j.eururo.2012.02.036
  56. Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273–279. EDN: WABDWM doi: 10.32364/2587-6821-2021-5-5-273-279
  57. Krivoborodov GG, Tur EI, Shirin DA. Hyperactive bladder: concept of disease and paradigms in the treatment. Medical Council. 2021;(4): 121–126. EDN: XTOBZY doi: 10.21518/2079-701X-2021-4-121-126.
  58. Krivoborodov GG, Tur EI, Efremov NS, Shkolnikov ME. High doses of trospium chloride in patients with overactive bladder due to neurologic disease. The multicenter observational program resource. Consilium Medicum. 2015;17(12):64–67. EDN: VIMUTT
  59. Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82. doi: 10.1038/sc.2015.195
  60. Kuzmin IV. Personalized approach to pharmacotherapy of overactive bladder // Urology reports (St. Petersburg). 2023;13(3): 267–282. EDN: XJVYUG doi: 10.17816/uroved569404
  61. Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5(1):51–62. doi: 10.3978/j.issn.2223-4683.2015.12.07
  62. Abrams P, Amarenco G, Bakke A, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol. 2003;170(4 Pt 1):1242–1251. doi: 10.1097/01.ju.0000084623.65480.f8
  63. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. doi: 10.1097/01.ju.0000162035.73977.1c
  64. Krivoborodov GG, Kuzmin IV, Romikh VV. Аbobotulinum toxin A (Dysport) for the treatment of neurogenic detrusor overactivity. Urologiia. 2023;(2):122–129 (In Russ.) EDN: CBOGMK doi: 10.18565/urology.2023.2.122-129
  65. Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53(3):613–618. doi: 10.1016/j.eururo.2007.08.039
  66. Kessler TM, Buchser E, Meyer S, et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007;51(5):1357–1363. doi: 10.1016/j.eururo.2006.11.011
  67. Schneider MP, Gross T, Bachmann LM, et al. Tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. Eur Urol. 2015;68(5):859–867. doi: 10.1016/j.eururo.2015.07.001
  68. Alberti C. Quick note on tissue engineering-based surgical measures to treat patients with neurogenic bladder-due detrusor/sphincter dyssynergia. Ann Ital Chir. 2015;86(3):252–257.
  69. Salyukov RV, Kasatonova EV, Salyukova YuR, Pavlov AYu. Malignancy due to the neurogenic lower urinary tract dysfunction in patients with the traumatic spinal cord injury. Bulletin of the Medical Institute of Continuing Education. 2023;3(3):107–114. EDN: PZVZUB doi: 10.36107/2782-1714_2023-3-3-107-114
  70. Mehta S, Hill D, Foley N, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93(4):597–603. doi: 10.1016/j.apmr.2011.11.020
  71. Hamid R, Arya M, Wood S, et al. The use of the Memokath stent in the treatment of detrusor sphincter dyssynergia in spinal cord injury patients: a single-centre seven-year experience. Eur Urol. 2003;43(5):539–543. doi: 10.1016/s0302-2838(03)00137-4
  72. Pan D, Troy A, Rogerson J, et al. Long-term outcomes of external sphincterotomy in a spinal injured population. J Urol. 2009;181(2):705–709. doi: 10.1016/j.juro.2008.10.004
  73. Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99(4):749–752. doi: 10.1111/j.1464-410X.2006.06742.x
  74. Schumm K, Lam TB. Types of urethral catheters for management of short-term voiding problems in hospitalized adults: a short version Cochrane review. Neurourol Urodyn. 2008;27(8):738–746. doi: 10.1002/nau.20645
  75. Sevastyanov MA, Karasaeva LA, Bozhkov IA, et al. Use of different types of catheters for intermittent bladder catheterization. Bulletin of the Russian Society of specialists in medical and social expertise, rehabilitation and rehabilitation industry. 2024;(2):55–63. EDN: BNPIDI doi: 10.17238/issn1999-2351.2024.2.55-63
  76. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163(3):768–772.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2024


 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».